Literature DB >> 21438686

Reward, addiction, withdrawal to nicotine.

Mariella De Biasi1, John A Dani.   

Abstract

Nicotine is the principal addictive component that drives continued tobacco use despite users' knowledge of the harmful consequences. The initiation of addiction involves the mesocorticolimbic dopamine system, which contributes to the processing of rewarding sensory stimuli during the overall shaping of successful behaviors. Acting mainly through nicotinic receptors containing the α4 and β2 subunits, often in combination with the α6 subunit, nicotine increases the firing rate and the phasic bursts by midbrain dopamine neurons. Neuroadaptations arise during chronic exposure to nicotine, producing an altered brain condition that requires the continued presence of nicotine to be maintained. When nicotine is removed, a withdrawal syndrome develops. The expression of somatic withdrawal symptoms depends mainly on the α5, α2, and β4 (and likely α3) nicotinic subunits involving the epithalamic habenular complex and its targets. Thus, nicotine taps into diverse neural systems and an array of nicotinic acetylcholine receptor (nAChR) subtypes to influence reward, addiction, and withdrawal.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21438686      PMCID: PMC3137256          DOI: 10.1146/annurev-neuro-061010-113734

Source DB:  PubMed          Journal:  Annu Rev Neurosci        ISSN: 0147-006X            Impact factor:   12.449


  289 in total

Review 1.  The neurotoxic effects of continuous cocaine and amphetamine in Habenula: implications for the substrates of psychosis.

Authors:  G Ellison; S Irwin; A Keys; K Noguchi; G Sulur
Journal:  NIDA Res Monogr       Date:  1996

Review 2.  A neural substrate of prediction and reward.

Authors:  W Schultz; P Dayan; P R Montague
Journal:  Science       Date:  1997-03-14       Impact factor: 47.728

3.  Biochemical evidence for gamma-aminobutyrate containing fibres from the nucleus accumbens to the substantia nigra and ventral tegmental area in the rat.

Authors:  I Walaas; F Fonnum
Journal:  Neuroscience       Date:  1980       Impact factor: 3.590

Review 4.  Nicotine and endogenous opioids: neurochemical and pharmacological evidence.

Authors:  Maria Hadjiconstantinou; Norton H Neff
Journal:  Neuropharmacology       Date:  2010-11-22       Impact factor: 5.250

5.  Dissociation of dopamine release in the nucleus accumbens from intracranial self-stimulation.

Authors:  P A Garris; M Kilpatrick; M A Bunin; D Michael; Q D Walker; R M Wightman
Journal:  Nature       Date:  1999-03-04       Impact factor: 49.962

6.  Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment.

Authors:  Isabelle M Maisonneuve; Stanley D Glick
Journal:  Pharmacol Biochem Behav       Date:  2003-06       Impact factor: 3.533

7.  Dopamine enables in vivo synaptic plasticity associated with the addictive drug nicotine.

Authors:  Jianrong Tang; John A Dani
Journal:  Neuron       Date:  2009-09-10       Impact factor: 17.173

Review 8.  A role for brain stress systems in addiction.

Authors:  George F Koob
Journal:  Neuron       Date:  2008-07-10       Impact factor: 17.173

Review 9.  Brain dopamine and reward.

Authors:  R A Wise; P P Rompre
Journal:  Annu Rev Psychol       Date:  1989       Impact factor: 24.137

Review 10.  Behavioral dopamine signals.

Authors:  Wolfram Schultz
Journal:  Trends Neurosci       Date:  2007-04-02       Impact factor: 13.837

View more
  162 in total

1.  Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats.

Authors:  Thomas J Hopkins; Laura E Rupprecht; Matthew R Hayes; Julie A Blendy; Heath D Schmidt
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

Review 2.  Recent findings in the pharmacology of inhaled nicotine: Preclinical and clinical in vivo studies.

Authors:  Asti Jackson; Ben Grobman; Suchitra Krishnan-Sarin
Journal:  Neuropharmacology       Date:  2020-06-24       Impact factor: 5.250

3.  Cotinine conundrum--a step forward but questions remain.

Authors:  Margaret R Spitz; Christopher I Amos; Laura J Bierut; Neil E Caporaso
Journal:  J Natl Cancer Inst       Date:  2012-04-25       Impact factor: 13.506

Review 4.  Tobacco addiction and the dysregulation of brain stress systems.

Authors:  Adrie W Bruijnzeel
Journal:  Neurosci Biobehav Rev       Date:  2012-03-03       Impact factor: 8.989

5.  Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbens.

Authors:  Xiomara A Perez; J Michael McIntosh; Maryka Quik
Journal:  J Neurochem       Date:  2013-10-13       Impact factor: 5.372

6.  Neural Signatures of Cognitive Flexibility and Reward Sensitivity Following Nicotinic Receptor Stimulation in Dependent Smokers: A Randomized Trial.

Authors:  Elise Lesage; Sarah E Aronson; Matthew T Sutherland; Thomas J Ross; Betty Jo Salmeron; Elliot A Stein
Journal:  JAMA Psychiatry       Date:  2017-06-01       Impact factor: 21.596

Review 7.  Nicotinic acetylcholine receptors and nicotine addiction: A brief introduction.

Authors:  Ruthie E Wittenberg; Shannon L Wolfman; Mariella De Biasi; John A Dani
Journal:  Neuropharmacology       Date:  2020-07-29       Impact factor: 5.250

8.  Stimulant treatment of ADHD and cigarette smoking: a meta-analysis.

Authors:  Erin N Schoenfelder; Stephen V Faraone; Scott H Kollins
Journal:  Pediatrics       Date:  2014-05-12       Impact factor: 7.124

9.  Methylphenidate does not influence smoking-reinforced responding or attentional performance in adult smokers with and without attention deficit hyperactivity disorder (ADHD).

Authors:  Scott H Kollins; Erin Schoenfelder; Joseph S English; F Joseph McClernon; Rachel E Dew; Scott D Lane
Journal:  Exp Clin Psychopharmacol       Date:  2013-10       Impact factor: 3.157

10.  Age-related differences in working memory deficits during nicotine withdrawal.

Authors:  Mary Falcone; E Paul Wileyto; Kosha Ruparel; Raphael T Gerraty; Leah LaPrate; John A Detre; Ruben Gur; James Loughead; Caryn Lerman
Journal:  Addict Biol       Date:  2013-03-18       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.